Loading…
AAALAC-accreditedUSDA-licensedOLAW-assuredPreclinical research & animal resources for global programs +1 (843) 589-5190 info@alphagenesisinc.com
Research animal retirement and lifetime care, now available through Alpha Genesis. Professionally managed lifetime care for retired research primates, with expert social reintroduction into stable outdoor groups led by veterinary staff deeply experienced in laboratory-animal medicine.
Learn more
Integrated Preclinical Development
Tell us what you are developing, what you already know and what decision you need to make next. Alpha Genesis can build the preclinical plan, design the studies, execute the work and carry the program through subsequent development stages.
Bring the molecule and the question. We work out which studies answer it and in what order. The plan starts with the decision you are trying to reach, not a fixed list of tests.
From there, one team owns the science through to the data, so the program moves as a single line of work rather than a set of disconnected studies.
How the program runs
We review what you are developing, the data you have and the decision you need to reach.
We define the sequence of studies that gets you to your next decision point.
We write the protocols, select the models, set the endpoints and size the cohorts.
We run the in vivo work in rodents and nonhuman primates under one program.
We generate the bioanalytical, pathology and molecular data the studies require.
We interpret the results with you and confirm what they mean for the program.
We design and run the follow-on work that the data indicate.
We carry the program into GLP toxicology and the IND-enabling package.
What one team means
The studies, the assays and the analysis all sit inside Alpha Genesis. The program is planned and delivered by the same team from start to finish.
Pharmacology, efficacy and safety studies in rodent and nonhuman primate models under one program.
Single and repeat-dose pharmacokinetics, exposure-response and target engagement.
Tissue distribution and clearance across dose levels and time points.
Acute and repeat-dose toxicology and safety pharmacology, GLP and non-GLP.
Quantitation by LC-MS/MS and ligand-binding assays with method development and validation.
Histology, immunohistochemistry and board-certified pathology read-outs.
qPCR, flow cytometry and cellular assays supporting mechanism and biomarker endpoints.
Imaging, telemetry, ECG and blood-pressure monitoring integrated into study endpoints.
One team plans the work, runs the studies and holds the timeline for the whole program.
Discuss your program
Tell us what you are developing, what you already know and where you are trying to get to. Our scientific and business-development team will review it and follow up to discuss the plan.
Please share only non-confidential information at this stage. We can put a confidentiality agreement in place before discussing the program in detail.